Skip to main content

Table 1 Patient characteristics

From: Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study

  BP Dataset TC Dataset
  n(%) or mean ± SD n(%) or mean ± SD
Number of patients 991 956
Female 879 (88.7%) 849 (88.8%)
Race   
   Caucasian 70% 70%
   Black 11% 11%
   Asian 11% 11%
   Other 8% 8%
CAD events   
MI
Angina
25
75
20
71
   Sudden cardiac death 2 2
   Total 94 86
Agea   
   At diagnosis 31.0 ± 13.8 30.9 ± 13.8
   At study entry 37.1 ± 14.0 37.5 ± 14.1
Disease durationa   
   At first clinic visit 4.0 ± 5.8 4.0 ± 5.9
   At study entry 6.1 ± 7.9 6.6 ± 8.1
SLEDAI-2Kb   
   At first clinic visit 9.7 ± 7.7 9.6 ± 7.7
   At study entry 9.2 ± 7.5 8.3 ± 7.2
SLICC/ACR-DIc   
   At first clinic visit 0.3 ± 0.7 0.3 ± 0.7
   At study entry 0.5 ± 1.2 0.6 ± 1.2
Steroids at study entry 623 (63%) 625 (65.6%)
Antimalarials at study entryd 380 (38.5%) 385 (40.4%)
Immunosuppressivese   
   At study entry 235 (23.8%) 233 (24.5%)
Hypertension at study entryf 221 (22.3%) 212 (22.6%)
Hypercholesterolemia at study entryg 344 (41.8%) 408 (42.7%)
Diabetes at study entryh 28 (2.9%) 31 (3.3%)
Smoker at study entryi 190 (19.5%) 183 (19.5%)
Antihypertensive use   
   at study entryj 174/691 (25.2%) 174/699 (24.9%)
Lipid-lowering meds   
   at study entryk 23/440 (5.2%) 22/440 (5.0%)
  1. BP, blood pressure (mm Hg); CAD, coronary artery disease; MI, myocardial infarction; SD, standard deviation; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000; SLICC/ACR-DI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; TC, total plasma cholesterol (mmol/L). aYears. bScores range from 0 to 105, with higher scores indicating more-active disease. cScores range from 0 to 46, with higher scores indicating greater disease-related damage. dAntimalarials include chloroquine and hydroxychloroquine. eImmunosuppressives include methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, and cyclophosphamide. fDiastolic BP ≥90 or systolic BP ≥140 mm Hg or treatment with antihypertensive medication. gHypercholesterolemia was defined as cholesterol > 5.2 mmol/L or lipid-lowering therapy. hDiabetes was defined as fasting plasma glucose > 7.0 mmol/L or diabetes therapy. iCurrent smoking is defined as smoking an average of one or more cigarettes per day over the past month. jAll classes of antihypertensives including diuretics, β-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin type II receptor blockers. kHMG Co-A reductase inhibitors (statins)